Drug Approval | November 23, 2023
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
It is only the second healthcare provider in the world to attain the Stage 6 DIAM certification.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)